Premium
Oral misoprostol for the management of incomplete abortion in Ecuador
Author(s) -
Montesinos Rolando,
Durocher Jill,
León Wilfrido,
Arellano Mónica,
Peña Melanie,
Pinto Ernesto,
Winikoff Beverly
Publication year - 2011
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2011.06.015
Subject(s) - misoprostol , medicine , abortion , incomplete abortion , vacuum aspiration , obstetrics , adverse effect , patient satisfaction , randomized controlled trial , family planning , pregnancy , population , surgery , research methodology , genetics , environmental health , biology
Objective To assess the feasibility of introducing misoprostol for the treatment of incomplete abortion in Quito, Ecuador. Methods In a randomized prospective study conducted at a large tertiary‐level maternity hospital and a private secondary‐level clinic between November 2006 and November 2007, women with incomplete abortion were treated with either 600 μg of oral misoprostol (n = 122) or manual vacuum aspiration (MVA) (n = 120). All participants were requested to return for follow‐up care on day 7 to determine the success of the treatment and to document their satisfaction with the method and the adverse effects experienced. Results Sixteen percent of women (39/242) did not return for their follow‐up visit and their outcomes are unknown. Among those who did return, 94% (100/106) of women showed successful completion of abortion after treatment with misoprostol, as compared with 100% (97/97) of women treated with MVA. Most women described their adverse effects after treatment as tolerable (misoprostol, 95%; MVA, 91%). Nearly all women reported being satisfied with their treatment (196/203); there were no differences among the women's reports of satisfaction according to treatment received. Conclusion An oral dose of 600 μg of misoprostol was found to be an acceptable and effective non‐surgical option for treating incomplete abortion. Clinical trials.gov NCT00674232.